Logo

CRBU

Caribou Biosciences, Inc.

CRBU

Caribou Biosciences, Inc. • NASDAQ
$1.94 ▲ 3.19% (+0.06)
Market Cap $180.32 M
52w High $3.54
52w Low $0.66
Dividend Yield 0%
P/E -1.14
Volume 317.95K
Outstanding Shares 92.95M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $2.198M ▼ $30.967M ▼ $-27.548M ▲ -1.253K% ▲ $-0.3 ▲ $-26.917M ▲
Q2-2025 $2.667M ▲ $50.245M ▲ $-54.098M ▼ -2.028K% ▼ $-0.58 ▼ $-34.261M ▲
Q1-2025 $2.353M ▲ $45.266M ▲ $-39.991M ▼ -1.7K% ▲ $-0.43 ▼ $-41.748M ▼
Q4-2024 $2.077M ▲ $11.088M ▼ $-35.49M ▼ -1.709K% ▲ $-0.39 ▼ $-37.091M ▼
Q3-2024 $2.024M $40.262M $-34.684M -1.714K% $-0.38 $-37.061M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $147.259M ▼ $194.984M ▼ $53.139M ▼ $141.845M ▼
Q2-2025 $183.948M ▼ $220.903M ▼ $54.771M ▼ $166.132M ▼
Q1-2025 $208.465M ▼ $273.656M ▼ $56.434M ▼ $217.222M ▼
Q4-2024 $209.537M ▼ $313.313M ▼ $60.362M ▼ $252.951M ▼
Q3-2024 $228.178M $344.334M $63.131M $281.203M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-27.548M ▲ $-25.185M ▲ $10.851M ▼ $277K ▲ $-14.057M ▼ $-25.3M ▲
Q2-2025 $-54.098M ▼ $-28.258M ▲ $24.036M ▼ $6K ▼ $-4.216M ▼ $-28.676M ▲
Q1-2025 $-39.991M ▼ $-36.725M ▼ $49.381M ▲ $468K ▼ $13.124M ▲ $-37.767M ▼
Q4-2024 $-35.49M ▼ $-35.47M ▼ $15.93M ▼ $3.863M ▲ $-15.677M ▼ $-35.988M ▼
Q3-2024 $-34.684M $-32.661M $26.521M $244K $-5.896M $-33.334M

Revenue by Products

Product Q1-2025Q2-2025Q3-2025
Reportable Segment
Reportable Segment
 $0 ▲$0 ▲$0 ▲

Five-Year Company Overview

Income Statement

Income Statement Caribou is still very much in the development phase, with only token revenue and no commercial products yet. The income statement is dominated by research and development and other operating costs, leading to consistent annual losses since before the IPO. Those losses have generally grown as the company has scaled its pipeline and platform work, which is typical for a clinical‑stage biotech but means profitability is not in sight. The path to improving this picture depends almost entirely on successful trial results and future partnerships or product launches, not on current operations.

Balance Sheet

Balance Sheet The balance sheet shows a science‑driven company funded mainly by equity rather than heavy borrowing. Caribou has a solid base of assets and shareholder equity, but cash has trended down as it spends on trials and infrastructure. Debt is present but still modest compared with the overall size of the company, which reduces financial strain from interest payments. Overall, the balance sheet offers some cushion to keep funding R&D, but that cushion will shrink over time unless the company raises additional capital or signs significant partnerships.

Cash Flow

Cash Flow Cash flows reflect a typical early‑stage biotech profile: steady cash outflow from operations as the company spends on research, clinical trials, and overhead. Free cash flow is clearly negative and has become more so as programs advance, showing a continuing cash burn. Capital spending is relatively light; the main drain is day‑to‑day operating and R&D activity, not large equipment or facilities projects. This means the company’s runway hinges on its starting cash balance and future fund‑raising rather than internally generated cash.

Competitive Edge

Competitive Edge Caribou operates in one of the most competitive corners of biotech: off‑the‑shelf cell therapies and gene editing. Its key strengths are a highly differentiated CRISPR platform, a strong patent position, and association with world‑class scientific leadership. At the same time, it faces well‑funded rivals developing similar allogeneic CAR‑T approaches, and any clinical setbacks or stronger data from competitors could quickly shift perceptions of its position. The decision to narrow the pipeline and focus on the most advanced oncology programs sharpens its story but also concentrates risk in fewer assets.

Innovation and R&D

Innovation and R&D Innovation is the center of Caribou’s identity. Its proprietary chRDNA platform aims to improve the precision and sophistication of genome editing, allowing complex “armoring” of cell therapies that could translate into better safety and durability. The company has deliberately concentrated R&D spending on a smaller number of late‑stage programs, stepping back from earlier‑stage projects to extend its cash runway. This focused approach increases the impact of each trial readout: if the lead programs succeed, the platform’s value is strongly validated; if they stumble, there are fewer backup shots on goal in the near term.

Summary

Caribou is a high‑science, high‑risk clinical‑stage biotech with minimal revenue, ongoing losses, and a clear dependence on external financing over time. Its balance sheet and cash position provide room to keep advancing key programs, but persistent cash burn will remain a central issue until there is either a major partnership, licensing deal, or eventual commercialization. The company’s real value driver is its chRDNA gene‑editing platform and the lead oncology cell therapies built on top of it, set within a crowded and fast‑moving competitive field. Future outcomes will hinge on clinical data quality, safety, durability of responses, and the company’s ability to convert scientific strength into sustainable business value.

NEWS

November 12, 2025 · 4:05 PM UTC

Caribou Biosciences Reports Third Quarter 2025 Financial Results and Provides Business Update

Read more

November 3, 2025 · 5:15 PM UTC

Caribou Biosciences to Participate in Upcoming Investor Conferences

Read more

November 3, 2025 · 7:00 AM UTC

Caribou Biosciences Announces Positive Data from ANTLER Phase 1 Trial Demonstrating Efficacy and Durability of Vispa-cel (CB-010), an Allogeneic CAR-T Cell Therapy, on Par with Autologous CAR-T Cell Therapies

Read more

November 2, 2025 · 4:00 PM UTC

Caribou Biosciences to Host Webcast to Report New Data Updates from Two Allogeneic CAR-T Cell Therapy Programs in Lymphoma and Multiple Myeloma

Read more